Stockscreener 앱 받기
35.65
0.17%
0.06
시간 외 거래:
35.92
0.27
+0.76%
전일 마감가:
$35.59
열려 있는:
$35.785
하루 거래량:
2.34M
Relative Volume:
0.60
시가총액:
$15.02B
수익:
$2.26B
순이익/손실:
$1.09B
주가수익비율:
15.21
EPS:
2.3431
순현금흐름:
$2.70B
1주 성능:
-1.63%
1개월 성능:
+2.27%
6개월 성능:
+17.66%
1년 성능:
+26.69%
1일 변동 폭
$35.51
$35.92
1주일 범위
$35.24
$36.89
52주 변동 폭
$24.05
$36.89
로열티 파마 Stock (RPRX) Company Profile
명칭
Royalty Pharma Plc
전화
(212) 883-0200
주소
110 EAST 59TH STREET, NEW YORK, NY
RPRX을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
RPRX
Royalty Pharma Plc
|
35.65 | 15.27B | 2.26B | 1.09B | 2.70B | 2.3431 |
|
VRTX
Vertex Pharmaceuticals Inc
|
458.49 | 121.30B | 11.10B | -988.90M | -1.26B | -3.92 |
|
REGN
Regeneron Pharmaceuticals Inc
|
545.53 | 61.60B | 14.09B | 4.50B | 2.96B | 39.28 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
320.52 | 41.17B | 2.35B | -269.70M | -75.39M | -2.09 |
|
ARGX
Argen X Se Adr
|
566.14 | 34.35B | 2.58B | 1.06B | -1.28B | 16.33 |
|
ONC
Beone Medicines Ltd Adr
|
291.93 | 27.29B | 3.81B | -644.79M | -669.77M | -6.24 |
로열티 파마 Stock (RPRX) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2025-05-16 | 개시 | Morgan Stanley | Overweight |
| 2024-06-03 | 다운그레이드 | UBS | Buy → Neutral |
| 2022-06-14 | 재개 | UBS | Buy |
| 2022-05-13 | 개시 | Scotiabank | Sector Outperform |
| 2022-04-27 | 개시 | Goldman | Buy |
| 2022-04-14 | 업그레이드 | JP Morgan | Neutral → Overweight |
| 2022-04-06 | 재개 | Morgan Stanley | Overweight |
| 2021-10-29 | 업그레이드 | Citigroup | Neutral → Buy |
| 2021-07-30 | 개시 | Tigress Financial | Buy |
| 2020-11-09 | 업그레이드 | UBS | Neutral → Buy |
| 2020-07-14 | 개시 | Evercore ISI | In-line |
| 2020-07-13 | 개시 | BofA Securities | Buy |
| 2020-07-13 | 개시 | Citigroup | Neutral |
| 2020-07-13 | 개시 | Cowen | Outperform |
| 2020-07-13 | 개시 | Goldman | Neutral |
| 2020-07-13 | 개시 | JP Morgan | Neutral |
| 2020-07-13 | 개시 | Morgan Stanley | Equal-Weight |
| 2020-07-13 | 개시 | SunTrust | Buy |
| 2020-07-13 | 개시 | UBS | Neutral |
모두보기
로열티 파마 주식(RPRX)의 최신 뉴스
What drives Royalty Pharma plc stock priceExtraordinary profit generation - Autocar Professional
Los Angeles Capital Management LLC Grows Holdings in Royalty Pharma PLC (NASDAQ:RPRX) - MarketBeat
Royalty Pharma plc Stock Analysis and ForecastConsistent triple returns - Autocar Professional
Royalty Pharma PLC (NASDAQ:RPRX) Stake Raised by Victory Capital Management Inc. - MarketBeat
Is Royalty Pharma plc a good long term investmentFree Trend-Following Techniques - jammulinksnews.com
What analysts say about Royalty Pharma plc stockTriple returns potential - PrintWeekIndia
Edgestream Partners L.P. Invests $659,000 in Royalty Pharma PLC (NASDAQ:RPRX) - MarketBeat
Morgan Stanley Raises Royalty Pharma (RPRX) Price Target, Maintains Overweight Rating - MSN
Royalty Pharma (NASDAQ:RPRX) Reaches New 52-Week HighTime to Buy? - MarketBeat
Cullen Frost Bankers Inc. Has $7.72 Million Stock Holdings in Royalty Pharma PLC (NASDAQ:RPRX) - MarketBeat
C WorldWide Group Holding A S Makes New Investment in Royalty Pharma PLC (NASDAQ:RPRX) - MarketBeat
Royalty Pharma Declares Q3 2025 Dividend of $0.22 per Class A Share - AInvest
Royalty Pharma Declares Q3 2025 Dividend of $0.22 per Class A Ordinary Share - AInvest
Royalty Pharma PLC Announces Quarterly Dividend of $0.22 (NASDAQ:RPRX) - MarketBeat
Royalty Pharma Declares Third Quarter 2025 Dividend - The Globe and Mail
Royalty Pharma announces $0.22 per share dividend for Q3 2025 - Investing.com
Royalty Pharma plc (RPRX) Declares $0.22 Quarterly Dividend; 2.5% Yield - StreetInsider
Royalty Pharma Announces Q3 2025 Dividend of $0.22 per Share - AInvest
How to Take Advantage of moves in (RPRX) - news.stocktradersdaily.com
Bryn Mawr Capital Management LLC Boosts Stock Position in Royalty Pharma PLC (NASDAQ:RPRX) - MarketBeat
Is Royalty Pharma plc stock a good hedge against inflationHigh Potential Safe Trades - Newser
Royalty Pharma adds two independent directors to board By Investing.com - Investing.com South Africa
Royalty Pharma Appoints Carole Ho and Elizabeth Weatherman to the Company’s Board of Directors - The Manila Times
Royalty Pharma adds two independent directors to board - Investing.com
Royalty Pharma Appoints Two New Independent Directors, Boosting Independent Board Representation to Over 90% - Quiver Quantitative
Royalty Pharma Appoints Denali CMO and Warburg Pincus Veteran to Board Following Major Acquisition - Stock Titan
Strata Wealth Advisors LLC Invests $387,000 in Royalty Pharma PLC (NASDAQ:RPRX) - MarketBeat
Cerity Partners LLC Increases Stock Position in Royalty Pharma PLC (NASDAQ:RPRX) - MarketBeat
Bank of New York Mellon Corp Has $45.53 Million Stock Holdings in Royalty Pharma PLC (NASDAQ:RPRX) - MarketBeat
Royalty Pharma to Announce Second Quarter 2025 Financial Results on August 6, 2025 - The Manila Times
Why Royalty Pharma plc stock attracts strong analyst attentionDaily Swing Candidates - Newser
How Royalty Pharma plc stock performs during market volatilityMarket Timing Advice - beatles.ru
What makes Royalty Pharma plc stock price move sharplyFree Trading Group - Newser
M&T Bank Corp Increases Stock Position in Royalty Pharma PLC (NASDAQ:RPRX) - Defense World
Fiera Capital Announces the Termination of imaxx Canadian Fixed Pay Fund and of imaxx Short Term Bond Fund - The Globe and Mail
Bank of New York Mellon Corp Has $45.53 Million Stake in Royalty Pharma PLC (NASDAQ:RPRX) - Defense World
Rehmann Capital Advisory Group Purchases Shares of 17,649 Royalty Pharma PLC (NASDAQ:RPRX) - MarketBeat
D.A. Davidson & CO. Trims Position in Royalty Pharma PLC (NASDAQ:RPRX) - MarketBeat
Royalty Pharma (NASDAQ:RPRX) Hits New 1-Year HighTime to Buy? - MarketBeat
Teacher Retirement System of Texas Sells 12,028 Shares of Royalty Pharma PLC (NASDAQ:RPRX) - MarketBeat
Royalty Pharma stock hits 52-week high at 36.44 USD By Investing.com - Investing.com South Africa
Royalty Pharma PLC (NASDAQ:RPRX) Stake Lessened by China Universal Asset Management Co. Ltd. - MarketBeat
Royalty Pharma stock hits 52-week high at 36.44 USD - Investing.com
로열티 파마 (RPRX) 재무 분석
매출
순이익
현금흐름
주당 순 이익
0.87%
0.22%
자본화:
|
볼륨(24시간):